Notice of Closed Meeting, 5445 [2019-02949]

Download as PDF 5445 Federal Register / Vol. 84, No. 35 / Thursday, February 21, 2019 / Notices 1999–2002, 2007–08, 2009–10, 2011–12 complete set Total costs Materials and Equipment—contractor: Plates, reagents, assays, aliquoting and packaging samples; use of equipment ...................................................................................................... Labor—contractor: Processing, handling, and shipping; NCHS: Data quality control ................ Proposal review and Administrative expenses—contractor: Inventory management and reporting; NCHS: Management of proposal process non-NCHS: Technical panel fees ............ Space—contractor: Freezer use and maintenance ..................................................................... Cost per sample .......................................................................................................................... Cost per new proposal: 1999–2002 ............................................................................................................................ 2007–2008 ............................................................................................................................ 2009–2010 ............................................................................................................................ 2011–2012 ............................................................................................................................ III ........................................................................................................................................... Cost per additional proposal: ** 1999–2002 ............................................................................................................................ 2007–2008 ............................................................................................................................ 2009–2010 ............................................................................................................................ 2011–2012 ............................................................................................................................ III ........................................................................................................................................... 1999–2002, 2007–08, 2009–10, 2011–12 partial set NHANES III complete set $1.51 4.98 $4.53 24.90 $0.75 2.49 3.02 5.59 15.10 6.04 5.59 41.06 1.51 2.79 7.55 118,369 69,641 73,884 62,605 ........................ * ........................ ........................ ........................ ........................ ........................ ........................ ........................ 54,050 ........................ 5,918 3,633 3,694 3,131 ........................ *** ........................ ........................ ........................ ........................ ........................ ........................ ........................ 2,702 ........................ * Cost calculated upon request. ** Additional research using DNA samples already obtained from previous solicitations. *** This charge will be 5 percent of the original cost. Note: Applicable CDC overhead and NCHS management and oversight charges will be added to these rates for proposals coming from Federal agencies. Dated: February 14, 2019. Sandra Cashman, Executive Secretary, Centers for Disease Control and Prevention. [FR Doc. 2019–02908 Filed 2–20–19; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention amozie on DSK3GDR082PROD with NOTICES1 Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and VerDate Sep<11>2014 17:08 Feb 20, 2019 Jkt 247001 Control Special Emphasis Panel (SEP)— RFA–CE–19–005, Research Grants for Preventing Violence and Violence Related Injury. Date: May 14–15, 2019. Time: 8:30 a.m.–5:30 p.m., EDT. Place: Atlanta Marriott Buckhead and Conference Center, 3405 Lenox Road NE, Atlanta, GA 30326. Agenda: To review and evaluate grant applications. For Further Information Contact: Mikel Walters, Ph.D., Scientific Review Official, NCIPC, CDC, 4770 Buford Highway NE, Mailstop F–63, Atlanta, Georgia 30341, Telephone (404) 639– 0913, MWalters@cdc.gov. The Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Sherri Berger, Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2019–02949 Filed 2–20–19; 8:45 am] BILLING CODE 4163–18–P PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—IP19–001, Surveillance for Respiratory Syncytial Virus (RSV) and Other Viral Respiratory Infections Among Native Americans/Alaskan Natives; IP19–002, Increasing Influenza and Tdap Vaccination of Pregnant Women in Obstetric/Gynecologic Practices in Large Health Systems Through Quality Improvement Interventions and IP19– 003, Understanding and Improving Immunization Services Among Adult Hospital Inpatient and Observation/ Clinical Decision Unit Settings; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—IP19– 001, Surveillance for Respiratory Syncytial Virus (RSV) and Other Viral Respiratory Infections Among Native Americans/Alaskan Natives; IP19–002, Increasing Influenza and Tdap Vaccination of Pregnant Women in Obstetric/Gynecologic Practices in Large Health Systems through Quality Improvement Interventions and IP19– 003, Understanding and Improving Immunization Services Among Adult Hospital Inpatient and Observation/ Clinical Decision Unit Settings; March 19–20, 2019; 10:00 a.m.–5:00 p.m., E:\FR\FM\21FEN1.SGM 21FEN1

Agencies

[Federal Register Volume 84, Number 35 (Thursday, February 21, 2019)]
[Notices]
[Page 5445]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-02949]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended, and the Determination of the Chief Operating 
Officer, CDC, pursuant to Public Law 92-463. The grant applications and 
the discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the grant applications, the 
disclosure of which would constitute a clearly unwarranted invasion of 
personal privacy.
    Name of Committee: Disease, Disability, and Injury Prevention and 
Control Special Emphasis Panel (SEP)--RFA-CE-19-005, Research Grants 
for Preventing Violence and Violence Related Injury.
    Date: May 14-15, 2019.
    Time: 8:30 a.m.-5:30 p.m., EDT.
    Place: Atlanta Marriott Buckhead and Conference Center, 3405 Lenox 
Road NE, Atlanta, GA 30326.
    Agenda: To review and evaluate grant applications.
    For Further Information Contact: Mikel Walters, Ph.D., Scientific 
Review Official, NCIPC, CDC, 4770 Buford Highway NE, Mailstop F-63, 
Atlanta, Georgia 30341, Telephone (404) 639-0913, MWalters@cdc.gov.
    The Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other committee 
management activities, for both the Centers for Disease Control and 
Prevention and the Agency for Toxic Substances and Disease Registry.

Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2019-02949 Filed 2-20-19; 8:45 am]
 BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.